


8EHQ-0395-13368

(A)

RECEIVED  
MAR 14 1995

95 MAR 14 AM 8:00



(1)

# COMPANY SANITIZED

March 6, 1995

Document Control Officer  
Office of Toxic Substances TS-790  
U.S. Environmental Protection Agency  
401 M Street SW  
Washington, DC 20460

**THIS CORRESPONDENCE CONTAINS  
CONFIDENTIAL BUSINESS INFORMATION  
UNDER TSCA SECTION 14**

## Notification of Substantial Risk Under TSCA §.8(e)

Dear Sir:

We are submitting information describing the acute oral toxicity of a substituted chlorophenol compound, 2-chloro-4-methylphenol, CASRN 6640-27-3 that is currently being used as a research material. Based on the June 1991 EPA TSCA 8(e) Reporting Guide, the estimated rat oral LD50 (33 mg/kg) would be classified in the "highly toxic" category which would allow only limited considerations for exposure.

The tested material is related to a much larger group of chlorinated phenolic compounds which have a wide variety of applications in the chemical industry. The tested material is not manufactured by us but is purchased from chemical distributors and is currently being used only for research purposes.

While we are reporting these data under TSCA 8(e), we do not feel that these findings are significant based on our understanding of the existing toxicity of other related chlorophenolic compounds, and that our use of this material in the US is limited exclusively for research purposes.

Following is a summary of the findings extracted from a draft report entitled "Acute Oral Toxicity Study with LD50 Estimation in the Rat", which has not yet been reviewed by our Quality Assurance Group. We will provide a copy of the final report once it has been issued.

The acute oral toxicity and LD50 of 2-chloro-4-methylphenol was evaluated in CrI:CDBR rats. Test material was administered via oral intubation at dose levels of 25, 50, 100, 1000 and 2000 mg/kg. Each dose group consisted of 5 animals/sex. Animals were observed for 14 days following dosing. In life signs (including hypoactivity, decreased food consumption, swollen abdomen, oral and nasal discharge, assorted respiratory abnormalities, etc.) were observed in all groups primarily from day 0 to day 6. The majority of the surviving animals were free of any adverse signs from day 4 to study termination (day 14). The combined oral LD50 was estimated as 32.73 mg/kg (44.43 mg/kg for males and 20.14 mg/kg for females). The majority of the animals that succumbed following test material administration died within one day of dosing. Both the incidence and onset of death were dose related. Postmortem findings included predominately gastrointestinal abnormalities/lesions (discoloration, sloughing, vascularization) which are indicative of severe irritation and/or corrosion.

If you have any questions, please feel free to contact  
send all formal correspondence on this report to my attention.

Please

We are claiming the company identification to be confidential business information; public disclosure of our identity would potentially cause economic damage by indicating research directions to our competitors.

8EHQ-95-13368

Sincerely,

68950000157

MMS  
3/27/95

# Triage of 8(e) Submissions

Date sent to triage: MAY 09 2009

NON-CAP

CAP

Submission number: 1348A

TSCA Inventory: C Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO            AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX            SBTOX            SEN            w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX            CTOX            EPI            RTOX            GTOX  
STOX/ONCO    CTOX/ONCO    IMMUNO            CYTO            NEUR

Other (FATE, EXPO, MET, etc.): \_\_\_\_\_

Notes:

**THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY**

<b>For Contractor Use Only</b>	
entire document: <u>0</u> 1 2 pages _____	pages <u>1</u>
Notes:	
Contractor reviewer: <u>FOR</u>	Date: <u>4/21/95</u>

CECATS TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: 0395-13368 (5) SEQ. A

TYPE: (INT) SUPP FLWT

SUBMITTER NAME: Confidential

SUB. DATE: 03/06/95 OTH DATE: 03/14/95 CSRAD DATE: 03/27/95

CHEMICAL NAME: CASE  
6640-27-3

- SECONDARY ACTIONS**
- 0401 INFO ACTION REQUESTED
  - 0402 STUDY'S PLANNED/IN PROGRESS
  - 0403 NOTIFY ACTION IN WORK IN PROGRESS
  - 0404 LABORATORY (TIAM) IS
  - 0405 PROFESSIONAL INQUIRY (TIAM) IS
  - 0406 APPROUSE DISCONTINUED
  - 0407 PRODUCTION DISCONTINUED
  - 0408 CONFIDENTIAL

- INFORMATION REQUESTED: FLWT DATE:**
- 0501 NO INFO REQUESTED
  - 0502 INFO REQUESTED (TECH)
  - 0503 INFO REQUESTED (VOL ACTIONS)
  - 0504 INFO REQUESTED (REPORTING RATIONALE)
- DISPOSITION:**
- 0601 REFER TO CHEMICAL SCREENING
  - 0602 CAP NOTICE

INFORMATION TYPE	P.F.C.	INFORMATION TYPE	P.F.C.
0201 ONCO (HUMAN)	01 02 04	0216 EPICLON	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECOAQUA TOX	01 02 04
0206 REPROTERATO (HUMAN)	01 02 04	0221 ENV. OCCURENCE	01 02 04
0207 REPROTERATO (ANIMAL)	01 02 04	0222 EMER INC OF ENV CONTAM	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQUEST DELAY	01 02 04
0209 NEURO (ANIMAL)	01 02 04	0224 PRODCOMP/CHEM ID	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04
0211 CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04
0212 ALUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)	01 02 04
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0229 METAPHARMACOD (ANIMAL)	01 02 04
0215 CHRONIC TOX (ANIMAL)	01 02 04	0230 METAPHARMACOD (HUMAN)	01 02 04

USE: Research

TOXICOLOGICAL CONCERN:

LOW  
MED  
HIGH

SPECIES: RAT

ONGOING REVIEW:

YES (DROP/REFER)  
NO (CONTINUE)

NON-ON INVENTORY:

YES  
NO

IN INVENTORY

Non-Cap  
contains CBI under TSCA section 14

-CPSS- 0927952113

0 0 0 0 0 0 0 0 0 0 0

> <ID NUMBER>

8(E)-13368A

> <TOX CONCERN>

H

> <COMMENT>

ACUTE ORAL TOXICITY IN RATS IS HIGH CONCERN BASED ON A MALE, FEMALE, AND COMBINED LD50 OF 44.43, 20.14, AND 32.73 MG/KG, RESPECTIVELY. 10 (5/SEX) ANIMALS WERE ADMINISTERED 25, 50, 100, 1000, OR 2000 MG/KG OF TEST MATERIAL. MORTALITIES OCCURRED BUT NO SPECIFIC NUMBERS WERE GIVEN. CLINICAL SIGNS INCLUDED HYPOACTIVITY, DECREASED FOOD CONSUMPTION, SWOLLEN ABDOMEN, ORAL AND NASAL DISCHARGE, AND ASSORTED RESPIRATORY ABNORMALITIES. NECROPSY REVEALED GI ABNORMALITIES INCLUDING DISCOLORATION, SLOUGHING, AND VASCULARIZATION. ONLY A SUMMARY WAS GIVEN.

\$\$\$\$